Tim-3 has previously been reported to be highly expressed in prostate cancer, hepatocellular carcinoma, and melanoma (Piao et al., 2014; Yan et al., 2015; Zheng et al., 2015; Tawk et al., 2016; Zhang et al., 2019). Here, HAVCR2 is linked to prostate carcinoma.